Repatha and Cannabis: The Interaction Profile Every Woman on a PCSK9 Inhibitor Should Understand

What Repatha Actually Does and Why Its Interaction Profile Is Unusual

Repatha works differently from statins, fibrates, or any other pill-based lipid therapy you may have taken before. It is a fully human monoclonal antibody that binds proprotein convertase subtilisin/kexin type 9 (PCSK9), a protein that would otherwise flag LDL receptors on your liver for destruction. By blocking PCSK9, Repatha keeps more LDL receptors active on the liver surface, pulling more LDL-C out of your bloodstream. The FOURIER trial enrolled 27,564 patients with established cardiovascular disease and showed that evolocumab reduced LDL-C by 59% and cut the composite of cardiovascular death, MI, or stroke by 15% versus placebo over a median of 2.2 years.

Why Pharmacokinetic Interactions Are Essentially Zero

Most drug interactions happen at the level of cytochrome P450 enzymes in the liver. Statins, many antihypertensives, hormonal contraceptives, and antidepressants all compete for the same enzymatic lanes. Evolocumab does not use those lanes. As a biologic, it is broken down by proteolytic degradation throughout body tissues, the same process that clears any protein. The Repatha prescribing information confirms no CYP-mediated metabolism and lists no formal drug-drug interactions based on pharmacokinetics.

Cannabis, specifically THC (delta-9-tetrahydrocannabinol) and CBD (cannabidiol), are substrates of CYP3A4 and CYP2C9 and inhibitors of CYP2C9 and CYP3A4 at higher doses. Those metabolic effects matter for drugs that share those pathways. Evolocumab is simply not one of them.

What "No PK Interaction" Does Not Mean

A clean pharmacokinetic profile is reassuring but incomplete. The question a clinician actually needs to answer is whether using cannabis alongside Repatha changes outcomes for the cardiovascular or metabolic condition you are treating. The answer there is less tidy.

The Pharmacodynamic Concerns: Where the Real Risk Lives

Even without a PK collision, cannabis and evolocumab overlap in the body systems that matter most.

Cardiovascular Effects of Cannabis in Women

Acute cannabis inhalation produces a sympathomimetic surge: heart rate climbs 20 to 100 percent within minutes and stays elevated for up to three hours, while blood pressure initially rises then may fall with repeated use. A 2020 analysis in the Journal of the American College of Cardiology identified cannabis use as an independent trigger for acute MI in young adults, with the risk window concentrated in the first hour after use.

Women's cardiovascular anatomy and hormonal physiology shape how these effects land. Premenopausal women with intact estrogen have some vascular protection, but that protection is not absolute and it disappears through perimenopause. By the time a woman is in her early 50s and her LDL is climbing fast enough to warrant PCSK9 inhibitor therapy, her arteries are more vulnerable to tachycardia-driven ischemia, not less. The combination of an already-elevated cardiovascular risk profile (which is why Repatha was prescribed) and the acute cardiac stress of cannabis inhalation deserves explicit conversation with your cardiologist.

Cannabis and Lipid Metabolism

This piece of the picture is genuinely complex, and the data in women is thin. A 2022 cross-sectional study in PLOS ONE found that current cannabis users had lower fasting triglycerides and slightly higher HDL-C compared with non-users after adjusting for confounders, which sounds favorable on the surface. But the same analysis showed no consistent benefit for LDL-C, and the population was predominantly young and metabolically healthy. Women on Repatha typically have familial hypercholesterolemia, established CVAD, or very high residual LDL despite maximally tolerated statins. Extrapolating a cross-sectional finding in healthy younger cannabis users to a 58-year-old postmenopausal woman with heterozygous familial hypercholesterolemia and a prior MI is a significant stretch.

Heavy or chronic cannabis use may also worsen insulin resistance in some individuals. Research published in Diabetes Care found that long-term heavy cannabis use was associated with increased fasting insulin and reduced insulin sensitivity in a dose-dependent pattern. Insulin resistance worsens the atherogenic dyslipidemia pattern, small dense LDL particles, high triglycerides, low HDL, that Repatha is trying to correct at the LDL level alone.

Endocannabinoid System, CB1 Receptors, and Metabolic Health

The endocannabinoid system has receptors throughout adipose tissue and the liver, and CB1 receptor activation by THC promotes lipogenesis and can increase hepatic triglyceride production. This effect is most pronounced with chronic high-dose use. For a woman whose Repatha prescription is one piece of a broader metabolic management plan (diet, statin, exercise, possibly a GLP-1 agonist), adding a stimulus that promotes hepatic fat production works against the therapeutic goal even when there is no PK interaction.

Can You Drink Alcohol on Repatha?

The short answer is that alcohol has no pharmacokinetic interaction with evolocumab for the same reason cannabis does not: Repatha bypasses hepatic CYP metabolism. Moderate alcohol use, defined by the 2020-2025 Dietary Guidelines for Americans as up to one drink per day for women, has a complex and somewhat paradoxical relationship with cardiovascular risk.

Where Alcohol Creates Problems in the Repatha Context

Heavy or binge alcohol use raises triglycerides, sometimes dramatically, and worsens liver function. If you are also on a statin alongside Repatha (the typical combination), heavy alcohol raises the already-low but real risk of statin-associated myopathy and hepatotoxicity. Alcohol also disrupts sleep, raises cortisol, promotes visceral fat accumulation, and worsens insulin resistance, all factors that make dyslipidemia harder to control regardless of how well Repatha is lowering your LDL.

For women specifically, alcohol metabolism is slower per unit of body weight because women have lower alcohol dehydrogenase activity and a higher body fat to water ratio. A single drink produces a higher blood alcohol concentration in a woman than the same drink in a man of the same body weight. This is not a moral statement. It is pharmacology. The American Heart Association does not recommend starting alcohol for cardiovascular benefit and advises women to stay at or below one drink per day if they choose to drink.

Repatha Across Women's Life Stages

Understanding how Repatha fits into your specific life stage is not a generic wellness point. It changes risk assessment, dosing discussion, and the safety of concurrent cannabis or alcohol use in ways that matter clinically.

Reproductive Years (Ages 18-40)

Women in their reproductive years are rarely prescribed Repatha unless they carry a familial hypercholesterolemia (FH) diagnosis, have homozygous FH, or have another very high-risk cardiovascular condition. ACOG Practice Bulletin No. 233 does not specifically address PCSK9 inhibitors, but general cardiovascular risk management in this age group is guided by underlying diagnosis. If you are in your 30s on Repatha for FH, the priorities are contraception (see below) and avoiding substances that add cardiovascular stress during an already-elevated-risk period.

Cannabis use in this age group is highest of any demographic. CDC data show approximately 20% of women aged 18-44 reported past-year cannabis use in recent surveillance cycles. If you are in this group and on Repatha, the pharmacokinetic picture is clean, but the cardiovascular pharmacodynamic concerns still apply, and pregnancy planning makes this conversation more urgent.

Perimenopause (Typically Ages 45-55)

Perimenopause is when LDL-C typically rises by 10-20% as estrogen falls, a change that can push previously borderline patients into ranges that warrant aggressive treatment. A longitudinal analysis from the SWAN study tracked women through the menopausal transition and documented a mean LDL increase of approximately 10.5 mg/dL in the two years around the final menstrual period.

This is the life stage when a Repatha prescription is most likely to begin. Cannabis use for sleep disruption and mood changes is common in perimenopause, often self-directed and not disclosed to clinicians. Adding cannabinoid-driven cardiovascular stress, lipid-metabolism disruption, and potential worsening of insulin resistance to an already metabolically turbulent transition warrants explicit, non-judgmental discussion with your prescribing clinician.

Postmenopause (After Final Menstrual Period)

Cardiovascular disease becomes the leading cause of death in women within a decade of menopause. Postmenopausal women on Repatha typically have established cardiovascular disease or very high 10-year ASCVD risk. Cannabis smoking in this group raises the same acute cardiac concerns as in any high-risk population, potentially more so given reduced vascular reserve. Edibles or tinctures avoid the acute sympathomimetic spike of inhalation but do not eliminate THC's CB1-mediated metabolic effects.

PCOS and Metabolic Syndrome

Women with PCOS have a higher prevalence of atherogenic dyslipidemia even in their 20s and 30s, driven by insulin resistance and hyperandrogenism. A meta-analysis in Fertility and Sterility found that women with PCOS had significantly higher LDL-C, triglycerides, and total cholesterol compared with age-matched controls. Some women with PCOS and very high LDL despite statin therapy end up on Repatha earlier than the general population. Cannabis use in PCOS is an under-studied area; the insulin-resistance-worsening potential of chronic THC exposure is a particular concern in a population already fighting that battle.

Pregnancy and Lactation: The Non-Negotiable Section

Evolocumab is not recommended during pregnancy. This is not a soft caution. It is a clear clinical position based on the mechanism of action and available animal data.

Human Pregnancy Data

Human data on evolocumab in pregnancy is extremely limited. Animal studies, specifically reproductive toxicology studies in monkeys at doses producing exposures several times the human therapeutic dose, showed no direct fetal harm, but PCSK9 plays a role in fetal lipid metabolism and cholesterol trafficking. The Repatha prescribing label acknowledges that the clinical significance of PCSK9 inhibition during fetal development is unknown and advises against use in pregnancy unless the benefit clearly outweighs uncertain fetal risk. Given that hypercholesterolemia itself is not acutely life-threatening in the short window of pregnancy, most clinicians and guidelines favor discontinuation before conception.

Contraception Requirements

Because of the unknown fetal risk and the long half-life of evolocumab (approximately 11-17 days), women of reproductive potential should use reliable contraception during treatment. If you are planning a pregnancy, discuss with your cardiologist how far in advance to stop Repatha and what bridge strategy (if any) will manage your lipid risk during that window. Statins, which are commonly co-prescribed with Repatha, are teratogenic and must also be stopped before conception. These conversations should happen proactively, not after a positive pregnancy test.

Lactation

The Repatha label states that it is unknown whether evolocumab is present in human milk, affects milk production, or affects the breastfed infant. As a large-molecule IgG antibody (molecular weight approximately 144 kDa), evolocumab is unlikely to transfer significantly into breast milk or survive neonatal gut digestion in meaningful amounts. Still, the data gap is real, and prescribers typically advise against use during breastfeeding until more is known. The decision should be made jointly between you and your clinician after weighing cardiovascular risk.

Cannabis in Pregnancy and Lactation

Cannabis use in pregnancy is associated with low birth weight, preterm birth, and adverse neurodevelopmental outcomes based on CDC-cited epidemiological data. THC is lipophilic and crosses the placenta. It is also excreted in breast milk at concentrations that can reach the infant. If you use cannabis and are pregnant, planning pregnancy, or breastfeeding, stopping cannabis is a separate and urgent priority from the Repatha question.

Who Repatha Is and Is Not Right for, by Life Stage and Condition

Likely Candidates

Women who typically qualify for Repatha include those with: heterozygous or homozygous familial hypercholesterolemia regardless of age, established atherosclerotic cardiovascular disease (prior MI, stroke, or peripheral artery disease) with LDL-C above 70 mg/dL despite maximally tolerated statin therapy, or very high 10-year ASCVD risk with statin intolerance. PCOS patients with FH overlap or established CVD may also qualify earlier in life.

Not a Good Fit

Repatha is not appropriate during pregnancy or breastfeeding, in women with no clear lipid or cardiovascular indication, or as a substitute for lifestyle intervention in low-to-moderate cardiovascular risk individuals who have not yet tried statin therapy. Women with known hypersensitivity to evolocumab or any component of the formulation should not use it.

Practical Guidance: What to Tell Your Clinician

Disclosure matters more than you might think. Cannabis and alcohol use change the clinical picture even when there is no direct PK interaction with Repatha. Here is what a complete disclosure conversation covers:

• Frequency and route of cannabis use (inhalation vs. Edible vs. Tincture, since the acute cardiovascular effects differ substantially)
• Whether you use cannabis primarily for sleep, pain, anxiety, or appetite (each maps to different risk considerations)
• Quantity and pattern of alcohol use, specifically whether you have any heavy-drinking or binge episodes
• Your current contraception method if you are of reproductive age
• Any hormonal therapies you are using (menopausal hormone therapy does not interact with Repatha pharmacokinetically, but it changes your overall cardiovascular risk calculation)

Your cardiologist or prescribing clinician cannot give you accurate guidance if they do not have accurate information.

Evidence Gaps: What We Do Not Know Yet

Women have historically been under-represented in cardiovascular drug trials. In FOURIER, approximately 25% of participants were women, meaning the dataset for sex-specific subgroup analysis is substantially smaller than for men. No published trial has specifically examined cannabis use patterns in women on PCSK9 inhibitor therapy and correlated that with cardiovascular outcomes. The lipid-metabolism data on cannabis is almost entirely from populations not selected for high cardiovascular risk. What we know about cannabis and lipids in young healthy users may not translate to a 55-year-old postmenopausal woman with familial hypercholesterolemia and a prior CABG.

This is an honest statement of uncertainty, not a reason to avoid the conversation with your clinician. Shared decision-making under uncertainty is possible. It just requires that the uncertainty be named.

A Note on Repatha Dosing and Monitoring

Evolocumab is given either as 140 mg subcutaneously every two weeks or 420 mg subcutaneously once monthly, both delivering equivalent LDL-C reduction of roughly 60% from baseline. Neither dose is adjusted for weight, sex, or renal/hepatic function in standard use. Injection site reactions are the most common adverse effect across the board. No dose adjustment is needed based on cannabis or alcohol use, since neither affects Repatha's pharmacokinetics. Monitoring focuses on fasting lipid panel, typically at 4-12 weeks after initiation and then every 3-12 months depending on your cardiologist's protocol, along with monitoring of the underlying cardiovascular condition.